Insights

Innovative Autism Solution JelikaLite is developing Cognilum, a non-invasive therapeutic device aimed at reducing autism symptoms and improving social integration, presenting a compelling opportunity to partner in early-stage medical technology sales and distribution.

Growing Market Focus With rising autism rates and a societal push to reduce long-term care costs, JelikaLite’s focus on home-based, cost-effective therapies aligns with market trends, offering potential sales growth in pediatric neurological health solutions.

Strategic Collaborations Partnership with Brain Scientific Inc. for clinical trials enhances credibility and visibility in clinical settings, providing sales teams with a foothold to establish relationships with healthcare providers and therapeutics centers.

Tech-Driven Approach JelikaLite’s integration of wearable devices, AI platforms, and near-infrared therapy opens avenues for selling complementary hardware, software, and monitoring services to hospitals, clinics, and telehealth providers.

Funding and Development Although current funding details are not disclosed, JelikaLite’s active development stage and recent media coverage indicate high growth potential, making it a strategic prospect for early investment or partnership opportunities within health tech markets.

JelikaLite Tech Stack

JelikaLite uses 8 technology products and services including RSS, JSON-LD, Priority Hints, and more. Explore JelikaLite's tech stack below.

  • RSS
    Content Management System
  • JSON-LD
    Javascript Frameworks
  • Priority Hints
    Performance
  • Yoast SEO
    Search Engines
  • Cloudflare Bot Management
    Security
  • Vimeo
    Video Players
  • Contact Form 7
    Web Platform Extensions
  • Apache HTTP Server
    Web Servers

JelikaLite's Email Address Formats

JelikaLite uses at least 1 format(s):
JelikaLite Email FormatsExamplePercentage
First.Last@jelikalite.comJohn.Doe@jelikalite.com
25%
First@jelikalite.comJohn@jelikalite.com
25%
First.Last@jelikalite.comJohn.Doe@jelikalite.com
25%
First@jelikalite.comJohn@jelikalite.com
25%

Frequently Asked Questions

Where is JelikaLite's headquarters located?

Minus sign iconPlus sign icon
JelikaLite's main headquarters is located at 30 Wall Street, 8th Floor New York, NY 10005, US. The company has employees across 1 continents, including North America.

What is JelikaLite's official website and social media links?

Minus sign iconPlus sign icon
JelikaLite's official website is jelikalite.com and has social profiles on LinkedInCrunchbase.

What is JelikaLite's NAICS code?

Minus sign iconPlus sign icon
JelikaLite's NAICS code is 3391 - Medical Equipment and Supplies Manufacturing.

How many employees does JelikaLite have currently?

Minus sign iconPlus sign icon
As of October 2025, JelikaLite has approximately 6 employees across 1 continents, including North America. Key team members include Chief Operating Officer: L. L.Co-Founder: E. S.. Explore JelikaLite's employee directory with LeadIQ.

What industry does JelikaLite belong to?

Minus sign iconPlus sign icon
JelikaLite operates in the Medical Equipment Manufacturing industry.

What technology does JelikaLite use?

Minus sign iconPlus sign icon
JelikaLite's tech stack includes RSSJSON-LDPriority HintsYoast SEOCloudflare Bot ManagementVimeoContact Form 7Apache HTTP Server.

What is JelikaLite's email format?

Minus sign iconPlus sign icon
JelikaLite's email format typically follows the pattern of First.Last@jelikalite.com. Find more JelikaLite email formats with LeadIQ.

When was JelikaLite founded?

Minus sign iconPlus sign icon
JelikaLite was founded in 2019.

JelikaLite

Medical Equipment ManufacturingUnited States2-10 Employees

Autism is a serious developmental disease that lasts a lifetime. The rates of autism continue to rise, the cause of the disease remains unknown and there is no cure. We believe that children on the autism spectrum can lead fulfilling and productive lives. That is why JelikaLite is developing Cognilum, an integrative solution with focus on pediatric neurological health using non-invasive novel therapies. 
Cognilum will enable children to integrate into society, parents to receive a home-based personalized cost-effective treatment while having a better quality of life, therapists to track progress and efficacy of existing interventions, and both payors and government to spend less money on special education and lifelong residential care. 
Cognilum may provide benefits that may be difficult to measure with money alone, yet society will bear the ultimate expenses if nothing continues to be done about the millions of children with autism and other neurological disorders who are unable to integrate into society.

Section iconCompany Overview

Headquarters
30 Wall Street, 8th Floor New York, NY 10005, US
NAICS Code
3391 - Medical Equipment and Supplies Manufacturing
Founded
2019
Employees
2-10

Section iconFunding & Financials

  • $1M$10M

    JelikaLite's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $1M$10M

    JelikaLite's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.